CL2009001311A1 - Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04). - Google Patents

Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04).

Info

Publication number
CL2009001311A1
CL2009001311A1 CL2009001311A CL2009001311A CL2009001311A1 CL 2009001311 A1 CL2009001311 A1 CL 2009001311A1 CL 2009001311 A CL2009001311 A CL 2009001311A CL 2009001311 A CL2009001311 A CL 2009001311A CL 2009001311 A1 CL2009001311 A1 CL 2009001311A1
Authority
CL
Chile
Prior art keywords
pyridin
methanone
chlorophenyl
bistrifluoromethylbenzyl
bistrifluoromethylbenzene
Prior art date
Application number
CL2009001311A
Other languages
English (en)
Inventor
Marie Reutzel-Edens Susan
Scott Coffey David
Wayne Pedersen Steven
Kaye Footman Pamela
Borghese Alflo
Lenyon Shella
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2009001311A1 publication Critical patent/CL2009001311A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (Div. Sol. 2680-04).
CL2009001311A 2003-10-24 2009-05-29 Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04). CL2009001311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
CL2009001311A1 true CL2009001311A1 (es) 2009-10-02

Family

ID=34549327

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2009001310A CL2009001310A1 (es) 2003-10-24 2009-05-29 Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04).
CL2009001311A CL2009001311A1 (es) 2003-10-24 2009-05-29 Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2009001310A CL2009001310A1 (es) 2003-10-24 2009-05-29 Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04).

Country Status (28)

Country Link
US (1) US7381826B2 (es)
JP (1) JP4959336B2 (es)
KR (1) KR100848407B1 (es)
CN (1) CN1863791B (es)
AR (1) AR046131A1 (es)
AT (1) ATE462700T1 (es)
AU (1) AU2004285855B8 (es)
BR (1) BRPI0415010B8 (es)
CA (1) CA2542140C (es)
CL (2) CL2009001310A1 (es)
CR (1) CR8353A (es)
DE (1) DE602004026333D1 (es)
DK (1) DK1675846T3 (es)
EA (1) EA008881B1 (es)
EC (1) ECSP066517A (es)
ES (1) ES2340772T3 (es)
HR (1) HRP20100207T1 (es)
IL (1) IL174926A0 (es)
MA (1) MA28329A1 (es)
MY (1) MY157375A (es)
NO (1) NO335090B1 (es)
NZ (2) NZ580480A (es)
PE (1) PE20050481A1 (es)
PT (1) PT1675846E (es)
TW (1) TW200524906A (es)
UA (1) UA82901C2 (es)
WO (1) WO2005042515A1 (es)
ZA (1) ZA200603234B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
KR102863233B1 (ko) 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체

Also Published As

Publication number Publication date
MY157375A (en) 2016-06-15
HRP20100207T1 (hr) 2010-05-31
AU2004285855B8 (en) 2011-04-28
UA82901C2 (en) 2008-05-26
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
CA2542140C (en) 2012-05-29
NO335090B1 (no) 2014-09-08
CN1863791A (zh) 2006-11-15
PT1675846E (pt) 2010-04-20
ES2340772T3 (es) 2010-06-09
JP4959336B2 (ja) 2012-06-20
EA200600829A1 (ru) 2006-08-25
NZ580480A (en) 2010-02-26
AU2004285855B2 (en) 2010-12-23
CL2009001310A1 (es) 2009-12-04
BRPI0415010B8 (pt) 2021-05-25
DK1675846T3 (da) 2010-05-31
BRPI0415010A (pt) 2006-11-07
JP2007509143A (ja) 2007-04-12
BRPI0415010A8 (pt) 2018-05-08
CA2542140A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
ZA200603234B (en) 2007-07-25
KR20060061388A (ko) 2006-06-07
ATE462700T1 (de) 2010-04-15
PE20050481A1 (es) 2005-09-20
US20070078166A1 (en) 2007-04-05
WO2005042515A1 (en) 2005-05-12
MA28329A1 (fr) 2006-12-01
IL174926A0 (en) 2006-08-20
NZ545917A (en) 2009-11-27
AR046131A1 (es) 2005-11-23
CR8353A (es) 2006-06-06
TW200524906A (en) 2005-08-01
KR100848407B1 (ko) 2008-07-28
BRPI0415010B1 (pt) 2019-07-09
CN1863791B (zh) 2011-12-07
EA008881B1 (ru) 2007-08-31
ECSP066517A (es) 2006-10-10
AU2004285855A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
CL2009001311A1 (es) Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04).
UA85693C2 (ru) Твердая фармацевтическая композиция для перорального применения, способ ее производства и ее применение
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
IL198775A0 (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
NL1023118A1 (nl) Werkwijze voor het doen van seismisch onderzoek.
NO20052474L (no) Amort form av esomeprazolsalter
ITBO20010141A0 (it) Macchina comprimitrice per la produzione di compresse
NL1024676A1 (nl) HIV integrase-remmers, farmaceutische preparaten en methoden voor het gebruik daarvan.
ITTO20000727A0 (it) Metodo di impostazione di un trattamento dialitico in una macchina per dialisi.
NO20032315L (no) 4-(bifenylkarbonylamino)piperidinderivater som MTP- inhibitorer
CY1112878T1 (el) Νεο αλας βενζοϋλογονανιδινης
DE60317675D1 (de) KRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-i1-(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL -1H-INDOL-3-YL -1H-PYRROLE MONO-HYDROCHLORIDE
ITBO20030374A1 (it) Metodo e struttura per la copertura di una macchina confezionatrice.
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
SV2002000134A (es) Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-[2-piperidin-1-il)etoxi]fenoxi)-2-(4-metoxifenil)benzo[b]tiofeno ref. x-13162t
ID26146A (id) Proses untuk cis-1-{2-[4-(6-metoksi-2-fenil-1,2,3,4-tetrahidronaftalen-1-il]fenoksi]etil} pirolidin
DK1613594T3 (da) 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridin derivater som serotonin-genoptagelseshæmmere
CY1107252T1 (el) Τρυγικο αλας παραγωγου της θειζολιδινοδιονης
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
EA200300345A1 (ru) Гидрохлоридная соль 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
ATE289194T1 (de) Eindämmung der wiederaufnahme von drogenmissbrauch
ITMI20030216A1 (it) Dispositivo di supporto di contenitori in macchine per il trattamento extracorporeo di sangue o in macchine per il trattamento di insufficienza renale.
IT1320358B1 (it) Procedimento e macchina per la realizzazione di piastre peraccumulatori.
NO20071096L (no) Diarylmetylpiperazinderivater, fremstillinger derav og anvendelser derav
FR2840896B1 (fr) Phenyl-et pyridyl-piperazines, procede pour leur preparation et compositions pharmaceutiques les contenant